Research Report University Hospital for clinical assessment OMB113676

Abstract

Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Keywords

• Follicular Lymphoma
• Ofatumumab
• Rituximab